Objectives: To examine the acceptability and initial efficacy of an emotional self-awareness treatment at reducing alexithymia and emotion dysregulation in participants with traumatic brain injury (TBI). Setting: An outpatient rehabilitation hospital. Participants: Seventeen adults with moderate to severe TBI and alexithymia. Time postinjury ranged 1 to 33 years. Design: Within subject design, with 3 assessment times: baseline, posttest, and 2-month follow-up. Intervention: Eight lessons incorporated psychoeducational information and skill-building exercises teaching emotional vocabulary, labeling, and differentiating self-emotions; interoceptive awareness; and distinguishing emotions from thoughts, actions, and sensations. Measures: Toronto Alexithymia Scale-20 (TAS-20); Levels of Emotional Awareness Scale (LEAS); Trait Anxiety Inventory (TAI); Patient Health Questionnaire-9 (PHQ-9); State-Trait Anger Expression Inventory (STAXI); Difficulty With Emotion Regulation Scale (DERS); and Positive and Negative Affect Scale (PANAS). Results: Thirteen participants completed the treatment. Repeatedmeasures analysis of variance revealed changes on the TAS-20 (P = .003), LEAS (P < .001), TAI (P = .014), STAXI (P = .015), DERS (P = .020), and positive affect (P < .005). Paired t tests indicated significant baseline to posttest improvements on these measures. Gains were maintained at follow-up for the TAS, LEAS, and positive affect. Treatment satisfaction was high. Conclusion: This is the first study published on treating alexithymia post-TBI. Positive changes were identified for emotional self-awareness and emotion regulation; some changes were maintained several months posttreatment. Findings justify advancing to the next investigational phase for this novel intervention. ments are often challenging to treat and ultimately become chronic problems for many survivors of TBI. These emotional sequelae typically have an adverse impact on psychosocial functioning, relationships, community reintegration, and quality of life.
ments are often challenging to treat and ultimately become chronic problems for many survivors of TBI. These emotional sequelae typically have an adverse impact on psychosocial functioning, relationships, community reintegration, and quality of life. [5] [6] [7] [8] [9] After a TBI, it is not unusual to have problems processing emotions. 10 Of particular interest here are emotion-processing deficits, characteristic of a psychological construct referred to as alexithymia. Quintessential features of alexithymia are poor awareness for personal emotions; reduced acknowledgement of physical sensations and association with emotional responses (eg, elevated heart rate and fear); difficulty describing and/or trouble distinguishing emotions (eg, differentiating anger from sad); and a preference for discussing concrete or superficial facts rather than emotions. 11 The prevalence of alexithymia after TBI ranges from 30% to 61% 10, 12, 13 compared with 10%
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There are several theoretical assumptions regarding the association of alexithymia with emotion dysregulation. One assumption is that emotional awareness is needed to consciously regulate emotions. 17 Also, reduced awareness and difficulty describing emotions have been associated with avoidant coping skills. 13 If one avoids a problem that causes emotional distress, that problem is likely to remain unresolved and may compound and/or surface through behavior. Furthermore, neuroimaging research suggests that the cognitive process of labeling emotions helps down regulate the emotional limbic reaction [18] [19] [20] [21] ; therefore, people who have trouble describing their emotions may have difficulty regulating unpleasant feelings.
There are currently no evidence-based, standard treatment approaches for reducing alexithymia after TBI. To date, there have been 2 publications examining a treatment specifically designed for alexithymia; neither of which were in the TBI population. One study involved 13 otherwise normal male participants with alexithymia (likely the result of poor developmental socialization). 22 Participants were taught an emotional vocabulary and to use an emotional diary to describe their feelings. Problems with alexithymia were significantly less after treatment. There was also a case study of a patient who had alexithymia after a stroke. This patient was similarly taught an emotional vocabulary, and in addition, video-feedback and heart rate biofeedback were used to enhance the patient's awareness for his own emotional responses. 23 This patient showed substantial reductions in alexithymia, suggesting that alexithymia may be minimized after brain damage with such targeted treatment.
Given the prevalence of alexithymia after TBI and associated negative outcomes, we developed a treatment to target characteristics of alexithymia in people with TBI. In adherence with recommendations for a phased developmental approach toward rehabilitation studies, which encourages appropriate preliminary studies before proceeding to randomized controlled trials, this study was designed as a phase I trial to examine proofof-concept and feasibility of this novel intervention. 24 Therefore, one aim was to examine initial efficacy on primary and secondary outcomes through changes in effect sizes. Primary outcomes were alexithymia and emotional awareness, whereas secondary outcomes pertained to emotion regulation variables (ie, anxiety, depression, anger, positive and negative affect, and general emotion dysregulation). With respect to feasibility, we were particularly interested in participant acceptability (satisfaction) with the program. A within-subject design with 3 assessment periods was used: baseline, immediate posttest, and 2-month follow-up. We hypothesized moderate to large effect sizes on our alexithymia and emotional awareness measures because we were explicitly teaching these skills. We had several hypotheses regarding the potential outcomes on emotion regulation. Based on the theories described earlier regarding the association of alexithymia with emotion dysregulation, one might expect that teaching emotional awareness and labeling skills would position participants to better regulate their emotions. Therefore, one hypothesis was that we would observe significant improvements in anxiety, depression, anger, affect, and overall emotion dysregulation. In contrast, it is possible that training emotional awareness and labeling would not generalize to emotion regulation because teaching emotional control was not part of treatment. Also, poor emotion regulation was not an inclusion criterion and therefore may not have been a problem for some participants. Another possibility is that changing behavior (emotion regulation) takes time and might not appear until follow-up. Alternatively, the immediate effect of newfound emotional self-awareness might be overwhelming and unpleasant for some individuals, and therefore result in an initial increase in anxiety, depression, or overall negative affect.
METHODS
Participants
When the goal of a study is to estimate initial effect sizes for the purposes of designing a larger trial, statistical guidelines recommend using a sample size of 12 for a pre-/postdesign. 25 In anticipation of a possible 20% dropout rate, we aimed to enroll a minimum of 15 participants. Recruitment letters were sent to current and former patients of a local rehabilitation hospital. Also, flyers were posted in the hospital's outpatient clinic and were disseminated at local brain injury support groups. Recruitment materials specified that we were looking for people who had had a moderate to severe TBI to participate in an investigational treatment study on emotional problems after brain injury. Many participants who were interested in the study initiated contacting us directly after receiving a recruitment letter or flyer; we also followed up recruitment letters with a phone call. Ultimately, we made phone contact with 72 people; 57% declined participation for the following reasons: not interested (44%); too busy (16%); felt they did not have emotional problems/need treatment (15%); had transportation challenges (15%); or had communication problems that would prohibit their participation (10%). Those who expressed interest in the study (n = 31) were prescreened; 25 participants passed prescreening criteria, of which 17 met the full study criteria and were enrolled into treatment.
Eligible participants had sustained a moderate to severe TBI, as defined by at least one of the criteria outlined by the Mayo classification system for TBI 26 : a Glasgow Coma Scale score of less than 13 (at the time of injury), posttraumatic amnesia 24 hours or 288 JOURNAL OF HEAD TRAUMA REHABILITATION/SEPTEMBER-OCTOBER 2017 more, loss of consciousness 30 minutes or more, or abnormal neuroimaging results consistent with moderate to severe brain injury. Participants were between 18 and 75 years old and were a minimum of 1-year post-TBI. Consistent with inclusion criteria, eligible participants had moderate to severe alexithymia (≥52 on the Toronto Alexithymia Scale-20 determined at screening). Participants were allowed to continue medications and ongoing therapies. They were excluded if they had a premorbid acquired brain injury (eg, stroke), neurological disorder (eg, autism), or a major psychiatric disorder (eg, schizophrenia) other than depression or posttraumatic stress disorder. Because depression and posttraumatic stress disorder are so common after TBI and strongly correlated with alexithymia, we did not exclude patients with these conditions to achieve a more representative sample. See Table 1 for details regarding participant demographics and relevant medical history.
Primary measures
Toronto Alexithymia Scale-20 11, 27 This self-report questionnaire measures total alexithymia, and 3 subconstructs: difficulty identifying feelings (awareness), difficulty describing feelings, and [10] [11] [12] [13] 15, 17 and is reported to have good internal consistency, validity, and test-retest reliability.
11,27
Levels of Emotional Awareness Scale 28 The Levels of Emotional Awareness Scale (LEAS) is a performance-based measure of emotional awareness and vocabulary. In response to 10 hypothetical scenarios, participants must say how they think they and a character in the scenario would feel. Responses were open ended and later entered into a computerized scoring system. 29 Scores range from 0 to 50, with higher scores indicating better emotional awareness and vocabulary. The LEAS consists of parallel versions (A and B). This test has been used in people with TBI. 30 The LEAS has significantly correlated with other measures of emotion perception and has good reliability indicators.
28,31
Secondary measures
State Trait Anxiety Inventory 32
This self-report measure has a State Anxiety scale, which inquires about feelings in that moment, and Trait Anxiety scale, which asks about general feelings over time. Scores range from 20 to 80 for each subscale. Higher scores indicate greater anxiety. Age and gender norms were used to convert raw scores to standard scores. For the purposes of this study, we only report trait anxiety scores. The State Trait Anxiety Inventory has been shown to have concurrent validity with other anxiety measures.
33
Patient Health Questionnaire-9 34 The Patient Health Questionnaire-9 (PHQ-9) is a selfreport assessment of depression with a Likert scale ranging from 0 to 3 (maximum score 27). Participants rate the frequency of specified problems during the past 2 weeks. The PHQ-9 has established validity and reliability.
35,36
State-Trait Anger Expression Inventory-2
This self-report assessment uses a 4-point Likert scale to measure 3 constructs: (1) state anger; (2) trait anger; and (3) behaviors and reactions when angry. Scores from these constructs are used to calculate an Anger Index T score (using age and gender norms), which provides an overall estimate of the person's likelihood to express anger outwardly or inwardly. The State-Trait Anger Expression Inventory (STAXI-2) has been shown to have good internal consistency. 37, 38 Positive and Negative Affect Scale 39 Using a 5-point scale, participants rate the extent to which they have experienced 10 positive mood states (Positive Affect) and 10 negative mood states (Negative Affect) during a specified time frame. The measure has shown good reliability and validity in a variety of populations. The scales are shown to be internally consistent and stable over several weeks.
39
Difficulty With Emotion Regulation Scale 40 Using a 5-point Likert scale, participants rate the frequency they utilize specific emotion regulation behaviors. There are 6 scales: Lack of Emotional Awareness, Lack of Emotional Clarity, Difficulties Controlling Impulsive Behaviors When Distressed, Difficulties Engaging in Goal-Directed Behavior When Distressed, Nonacceptance of Negative Emotional Responses, and Limited Access to Effective Emotion Regulation Strategies. Items are summed to provide a Total Emotion Dysregulation score. The Difficulty With Emotion Regulation Scale (DERS) has high internal consistency test-retest reliability and good construct validity. 40 
Satisfaction questionnaires
Satisfaction questions were created by the authors and administered at posttest and follow-up. Questions were designed to evaluate overall satisfaction; perceived relevance to their needs; implementation of strategies to their daily life; clarity of information; and translation to emotion regulation and quality of life. See Table 2 for questions and responses.
Intervention
The intervention was composed of 8 sessions involving psychoeducational lessons and skill-building exercises to accomplish the following goals: understand the benefits of emotional awareness; enhance emotional vocabulary; improve accuracy for describing personal emotions; acknowledge and differentiate multiple emotions; increase awareness for emotional responses, including changes in physical sensations; and distinguish emotions from thoughts, actions, and physical sensations. These objectives were chosen based on the aforementioned characteristics typically associated with alexithymia. A clinical research assistant (RA) delivered the treatment, which was composed of lessons that were presented on a computer through a third-party learning management system, Lesson.ly. The standardized treatment content was outlined on the computer and closely followed by the clinical RA. To make the sessions more engaging and natural, the treatment content was not read verbatim; the RA was given the liberty to paraphrase the content. The psycho-educational content was to be used as a guideline for points of discussion; the RA was instructed to address all of these points with the participant as part of their sessions. Elaborated discussions between the RA and participants were encouraged and focused on personalizing the content (ie, examine how the content applied to them). The RA had the liberty to determine which content needed more or less discussion based on the participants' performance on the session exercises. The first 4 lessons focused on teaching the principles underlying the key objectives, followed by interactive discussions and practice exercises. Lessons 5 through 8 were exercises that used first-person perspective videos simulating emotional scenarios to give participants the opportunity to practice processing their emotional responses to events (eg, getting yelled at by a boss in front of colleagues). See Table 3 . An emotional compass was used throughout training to guide participants' discovery of their emotions by leading them from vague emotional descriptors (eg, bad) to more specific emotions (eg, worried). The compass delineates emotions by valence (pleasant and unpleasant) and emotional arousal (high and low). Participants were given a notebook with the lessons, and take-home exercises for each session. Take-home lessons encouraged participants to personalize and incorporate the lessons into their daily life and to discuss what they learned with their family members.
Procedures
This study was registered on clinicaltrials.gov (NCT02432300) and approved by the institutional review board. Interested participants were prescreened on the telephone; those who met initial screening criteria were scheduled for baseline testing. All participants provided consent prior to baseline testing. At each testing point, the research assistant (RA) read the questions from the assessments to participants and hand-recorded their responses. Responses to the LEAS were written and audio-recorded for later verification of the subjects' responses. LEAS versions A and B were alternated between assessment time points. To minimize potential bias, the RA who conducted the participant's posttesting was always different from the RA who conducted that person's baseline testing. The "clinical RA" who was responsible for treatment administration never tested participants.
Baseline testing, posttest, and followup testing
Following consent, baseline testing involved a demographics and medical history questionnaire, followed by the TAS-20, LEAS, PHQ-9, Trait Anxiety Inventory (TAI), Positive and Negative Affect Scale (PANAS), DERS, and STAXI-2. Participants who scored 52 or more on the TAS-20 at baseline were enrolled into treatment. Posttesting occurred within 1 week of finishing the training program. Follow-up testing aimed to assess participants approximately 2 months after posttest; however, because of scheduling conflicts some follow-up testing occurred closer to 3 and 4 months later (mean 80.46; range 57-127 days). Baseline and posttesting always occurred in-person at the rehabilitation hospital, with the exception of the final assessments, which could be r Physical sensation awareness, emotional arousal, and association to emotions (Part I); exercises to increase awareness of heart rate, body temperature, breathing, body movement, and overall emotional arousal (eg, body scan) Lesson 4 r Physical sensation awareness and association to emotions (Part II) r Multiple emotions, differentiating emotions, and emotions beyond anger Simulated first-person point-of-view emotional scenarios, followed by discussions of thoughts, desired actions, physical sensations, and emotional responses in response to the scenarios. Afterward, participants described similar personal events and their emotions, thoughts, actions, and feelings response performed by telephone to minimize chances for lost to follow-up; 2 participants selected this option. Posttesting and follow-up testing involved all of the same assessments as baseline, minus the demographics and medical history form, and with the addition of the satisfaction questionnaire. Participants were also asked at posttest and follow-up about receipt of psychological counseling and any changes in medication.
Intervention
The clinical RA delivering the treatment was a 4th-year doctoral psychology student who had experience working with the TBI population. He was trained for 16 hours on treatment delivery, followed by 16 hours of observation and feedback. Sessions lasted between 60 and 90 minutes and were delivered individually to participants twice a week for 4 weeks. Treatment content was displayed on a computer to standardize the information to be covered. The material guided an interactive discussion between the clinical RA and participant. Participants completed skill-building exercises and quizzes on the computer. Visual aids were used to illustrate certain points.
Data analyses
Descriptive statistics were calculated for participant characteristics, injury-related variables, and all outcome variables. Associations of alexithymia with participant characteristics and injury-related variables were examined with Pearson correlations. Changes on outcome measures were calculated with repeated-measures analysis of variance (ANOVA). Greenhouse-Geisser was used to determine significance of within-subjects effects when Maulchy's test of sphericity was violated. When repeated measures of ANOVA were found significant, planned comparisons were calculated using paired t tests to evaluate changes from Time 1 (baseline) to Time 2 (posttest) and Time 1 to Time 3 (2-month follow-up). The α level for these comparisons was adjusted for 2 comparisons (α = 0.025). The percentage of participants who changed in level of severity on the TAS over the course of treatment is reported. Because the other primary outcome measure (LEAS) does not have normative data regarding categorical impairment levels like the TAS, we report the percentage of participants who obtained at least a 1 / 2 standard deviation change (effect size of 0.5). This level of change is considered to be a reasonable estimation of the minimal clinically important difference for a measure in the absence of more definitive determination of the minimal clinically important difference. 41 Because a primary goal of the study was to determine effect sizes, d Cohen effect sizes were calculated for all variables from Time 1 to Time 2 and Time 1 to Time 3 (0.2 = small; 0.5 = medium; and 0.8 = large effect sizes).
42
RESULTS
Participants
Of the 17 participants who were eligible and enrolled into the treatment, 13 participants completed the treatment, resulting in a 23.5% dropout rate. One person reported the day after his first session that he did not like the program, even though he indicated high satisfaction on the session satisfaction questionnaire; 2 said they could no longer do it (one after 5 sessions and the other after 1, despite positive feedback on their session satisfaction questionnaires); and the fourth participant had unrelated medical complications that interfered with study participation after his second session. There was a 100% retention rate at posttest and follow-up for the participants who completed the treatment.
Between baseline and pretest, 3 participants continued to receive ongoing psychological counseling (1-3 sessions), which had been initiated prior to enrollment; however, according to these participants, the sessions did not focus on improving emotional awareness. In terms of medication changes, 1 participant started an antibiotic. Between posttest and follow-up, 5 participants continued to receive ongoing psychological counseling, which had been initiated prior to enrollment; for 3 of these participants, sessions did address emotional awareness to some degree. Three participants changed medication between posttest and follow-up: 1 went off an antidepressant; 1 changed antidepressants from tricyclic antidepressant amitriptyline to serotonin reuptake inhibitor sertraline; and 1 started a pain medication.
Correlations calculated on the 17 enrolled participants showed no significant associations of alexithymia with sex, age, and years of education, years postinjury, self-reported duration of post-traumatic amnesia, or loss of consciousness duration (P > .05).
Posttreatment changes on primary outcome measures
Repeated measures of ANOVA showed significant improvements on the TAS-20 (alexithymia) and the LEAS (emotional awareness) over time. Additional t tests revealed that posttest and follow-up scores for both measures were significantly improved from baseline scores, even after adjusting for multiple comparisons (α = 0.025). Eight (62%) participants changed to a less severe alexithymia category on the TAS-20 at posttest, of which 6 were lowered to normal (<52); 5 of the 6 remained in the normal category at 2-month follow-up. Findings also revealed that 46.2% of participants improved by more than 0.5 standard deviation at posttest on the LEAS (≥6) and 61.5% showed this degree of improvement at 2-month follow-up. See Table 4 . 
Posttreatment changes on secondary outcome measures
Findings from the repeated measures of ANOVA showed significant improvements on the TAI (anxiety), STAXI (anger), positive affect, and DERS (emotion dysregulation) over time. Scores on the PHQ-9 (depression) and the negative affect measures did not change significantly. Greenhouse-Geisser was used to determine within-subject effects for the TAI and negative affect. Posttest scores were significantly better than baseline for the TAI, STAXI, positive affect, and the DERS; after adjusting for multiple comparisons (α = 0.025), all differences remained significant except the STAXI (P = .027). Two-month follow-up scores were significantly better than baseline for the TAI and positive affect; after adjusting for multiple comparisons the TAI was no longer significant (P = .038). See Table 4 .
Treatment satisfaction
Descriptive statistics were calculated for treatment satisfaction at the posttest and 2-month follow-up. Results indicate participants were largely satisfied with the treatment and felt the treatment helped them. See Table 2 .
DISCUSSION
Alexithymia and commonly related emotion dysregulation deficits are quite prevalent after TBI. [1] [2] [3] [4] 10, 12, 13 Although a few emotion regulation treatment studies in the TBI population have incorporated some emotional self-awareness training, it has typically been a small part of a holistic approach and changes in alexithymia were not evaluated. [43] [44] [45] [46] [47] Consequently, this is the first study to examine proof of concept for a treatment that focused primarily on improving components of alexithymia (eg, emotional awareness, labeling, and interoceptive awareness) in people with TBI.
Participants' emotional self-awareness and ability to describe and differentiate emotions were significantly improved immediately after treatment, and 2 months later. This suggests the benefits were maintained over time. As hypothesized, effect sizes for the TAS and LEAS were quite large at posttest, and medium to large 2 months later. Furthermore, 62% of participants reduced the categorical severity of their alexithymia, with 6 participants changing to "low" (normal) alexithymia at posttest, of which 5 remained in that category 2 months after treatment ended. Almost half (46.2%) of the participants had a clinically meaningful improvement on the LEAS.
Another goal of the study was to examine changes in emotion dysregulation posttreatment. Despite not being explicitly trained to regulate unpleasant emotions as part of this intervention, initial improvements were found for anxiety, positive affect, and overall emotion dysregulation, and there was a trend toward a reduction in anger. Two months posttreatment, significant improvements were maintained for positive affect, and a maintenance trend emerged for anxiety. Although some findings were no longer significant after correcting for multiple comparisons, it should be recalled that effect sizes, not statistical P values, were the primary concern for this phase I trial. Effect sizes immediately after treatment ranged from medium to large for alexithymia, emotional awareness, positive affect, anxiety, and overall emotion regulation (DERS); effect sizes were small for anger. Two months later, positive affect and anxiety effect sizes were still large and medium, respectively. Depression and negative affect did not change significantly at either time point. It is possible that scores on the PHQ-9 did not change substantially because items such as fatigue, sleep, and concentration, may not have actually been indicative of depression, but rather mere effects of the TBI that would not expect to be impacted by this treatment; potentially another measure of depression may have been more appropriate. However, another possibility is that the treatment had different effects on depression in different individuals. Upon closer inspection of the PHQ-9 scores, it appears depression increased for some and decreased for others, averaging to no change. It is possible that increased emotional selfawareness initially resulted in more depression for some individuals, suggesting depression should be monitored during this type of treatment.
When comparing the treatment effects on our primary and secondary outcomes, the distinction between emotional self-awareness and emotion regulation becomes apparent: we observed large immediate and longterm effects for the former, and a few shorter-lived changes for the latter. These preliminary findings suggest that improving emotional awareness and labeling can partially help people to better control some unpleasant emotions; however, it is not sufficient on its own to make a robust and lasting effect. This supports the notion that this type of training should be considered as a precursor or supplement to other techniques that explicitly teach patients how to regulate their emotions. Future work should further investigate the degree of impact that training emotional awareness has on emotion regulation, and to what degree emotion regulation needs to be specifically targeted.
Determining consumer acceptability of interventions is an important component of phase I clinical testing. Responses to posttreatment satisfaction questions, as seen in Table 2 , indicate that the 13 participants who completed the treatment were quite satisfied with the program. Ultimately 4 people withdrew from treatment; however, only 1 person withdrew from the program because he was dissatisfied with the treatment. The remaining 3 who withdrew from the program showed high satisfaction on their session satisfaction ratings. Unfortunately, 1 participant was unable to complete the program because of unrelated medical complications. The other 2 participants did not elaborate on their reasoning for withdrawing beyond saying they could no longer do it; however, both claimed their decision to withdraw was unrelated to the program. Future studies with ample sample size should continue to explore dropout rates and reasoning for withdraw to better understand consumer acceptance of this intervention.
Limitations
The lack of a control group, and not controlling for some potentially confounding variables (medication and outside counseling), clearly prevents us from making any cause-effect inferences about the treatment on the outcomes. It is possible that spending time with our clinical RA could have had an impact on participants' anxiety, positive affect, and overall emotion regulation. With respect to other counseling, their outside sessions during the alexithymia intervention did not focus on emotional awareness (according to the participants), and therefore unlikely the reason for their improvement on the TAS and LEAS at posttest. Furthermore, the fact that the outside sessions were a stable part of these participants' routines prestudy, combined with the low number of sessions between baseline and posttest, also reduce the likelihood they played a significant role in posttest changes.
The small sample size, although adequate to determine effect size, reduces generalization of these results to the larger TBI population. Small sample sizes and within-subject designs are considered appropriate for the exploratory stage of this novel intervention. This was a critical stepping-stone, justifying the time and money needed to execute a larger, more definitive study to determine the effectiveness of this novel treatment for alexithymia in the TBI population. Until an adequately powered randomized controlled trial substantiates these results, current findings should be viewed with caution.
Another study limitation is that most measures were subjective, and due to the nature of being alexithymic (poor emotional awareness), there may be some concern Copyright © 2017 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
www.headtraumarehab.com 294 JOURNAL OF HEAD TRAUMA REHABILITATION/SEPTEMBER-OCTOBER 2017 about their accuracy on the subjective emotional measures. However, it is important to note that even though people with alexithymia may not always be aware of their emotions in the moment, they are often able to acknowledge general emotional deficits. Most are generally aware they have problems with their own emotional awareness (an indicator that qualified them for the study), and are capable of acknowledging symptoms of anxiety, depression, and anger as they are described on these measures. That said, having input from caregivers or possibly some objective assessments for behavioral changes would have strengthened the study. However, if participants feel that they had fewer or less severe emotional problems after the treatment, this positive change in self-perception is also meaningful. Moreover, a change on the performance-based LEAS was an objective indicator of improved emotional awareness. Because alternate forms were used for the LEAS, it is unlikely these changes were due to a learning effect.
CONCLUSION
This is the first study to collectively examine posttreatment changes in alexithymia and emotion dysregulation in people with TBI. Posttreatment changes indicated moderate to large effects sizes, with improvements in alexithymia, emotional awareness, anxiety, positive affect, and overall emotion regulation. Some of these changes were maintained over 2 months. These preliminary findings are encouraging, especially because the treatment was only 8 sessions and participants were many years postinjury (average almost 9 years). However, further investigation is needed to have a more definitive understanding of the treatment effect. These promising results support the next phase of investigation involving a larger controlled study. If validated through a controlled study, this training program has the potential to have a substantial impact on the way emotion dysregulation deficits are treated after TBI. It is anticipated that this type of intervention would not be administered in isolation. If it is found that this treatment can help people with TBI effectively recognize and describe their emotions, additional studies should evaluate the benefit of adding it as a precursor to treatments that explicitly teach modification of unpleasant emotional responses (eg, cognitive behavioral therapy), to achieve a more robust effect on both emotion awareness and regulation.
